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Introduction: Severe community-acquired pneumonia is defined as community-acquired pneu-
monia that requires intensive medical care. Mortality in these patients is still high depending
on time and admission. Since bad outcomes may occur despite antibiotic therapy to treat se-
vere community-acquired pneumonia, the focus has shifted to targeting the host response. The
CIGMA Study examines the safety and efficacy of the novel IgM-enriched immunoglobulin prep-
aration BT086 when added to standard of care treatment.
Methods/design: The aim of this multicentre, randomised, placebo-controlled, double-blind,
parallel-group, adaptive group-sequential phase II study is to determine the efficacy and safety
of BT086, an IgM-enriched immunoglobulin preparation, as an adjunctive treatment in
mechanically-ventilated patients with severe community-acquired pneumonia. The increase
of ventilator-free days is the primary endpoint in this study. For this trial, ventilator-free days
are defined as the number of days between successful extubation from endotracheal ventila-
tion and day 28 after enrolment of the patient into the study. Two interim analyses were
considered for this study.
Discussion: Several novel agents for treatment of sepsis have been evaluated in the last two
decades; however, none has significantly reduced mortality rates. Failure was attributed to
the heterogeneity of septic patients or sepsis. Severe community-acquired pneumonia was
chosen as the indication for this study to increase homogeneity within this patient population.
Trial registration: EUDRACT 2010-022380-35.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The CIGMA (Concentrated IgM for Application) Study is a
multicentre, multi-national, randomised, placebo-
controlled, parallel-group, adaptive group-sequential
phase II study to determine the efficacy and safety of the
IgM-enriched immunoglobulin preparation BT086 as an
adjunctive treatment in severe community-acquired
pneumonia (sCAP).
Community-acquired pneumonia (CAP) occurring in in-
dividuals who have not recently been in hospital is a sig-
nificant cause of morbidity and mortality in adults. CAP
mortality rates are high and have not changed significantly
over the past several decades despite the availability of
improved broad-spectrum antibiotics [1,2]. CAP incidence
varies by geographic region, gender (more common in men
than in women), and age (more common in people aged
65 years). Mortality has been reported to vary from <1%
to 48% and is associated with advanced age, co-morbid
conditions, and CAP severity [3]. In the United States,
CAP is the number one cause of death from infectious dis-
eases and the eighth leading cause of death, with an esti-
mated 1.3 million hospitalisations each year and an
estimated cost of $40 billion [4].
sCAP is usually defined clinically as CAP that requires
intensive medical care. Up to 10% of hospitalized adult CAP
patients require intensive medical care and are transferred
to intensive care units (ICUs) [5] with great impact on
health care costs [3,6] and outcome. Mortality of sCAP
patients admitted to ICUs usually ranges from 35 to 58%
depending on time and admission to hospital [7]. However,
two recent trials on sCAP found a mortality rate of only
17.9% [ 8] and 23.1% [9].
A review published by Cillo´niz et al. [10] reported that
the aetiology for CAP was unknown in more than 50% ofcases despite the use of ever improving microbiological
techniques. The most common identified cause of CAP and
sCAP remains the bacterium Streptococcus pneumoniae
[3,10].
Widespread increased resistance of common respiratory
pathogens to antibiotics is becoming a major challenge in
treating this life-threatening condition [3,11].
Since bad outcomes may occur despite antibiotic ther-
apy in sCAP, attention has turned to targeting the host
response in an attempt to improve sCAP outcomes. This
approach is supported by the observation that systemic
cytokine response to pathogens leads to the progression of
sCAP, and the spectrum of circulating cytokines in hospi-
talised sCAP patients is indicative of elevated inflammation
in most cases, irrespective of sepsis [12]. Recombinant
tissue factor pathway inhibitors (rTFPI), activated protein C
(APC), corticosteroids, and intravenous immunoglobulins
have been investigated for their potential as adjunctive and
host-targeted treatments for sCAP [2].
The rTFPI tifacogin has been shown to restore regulation
of tissue factor pathways, reducingmortality, inflammation,
and lung injury in a number of animalmodels. After promising
initial results in small patient populations, a controlled trial
(2138 patients) was conducted with tifacogin in adults with
sCAP [8]. In this large trial tifacogin treatment had no mor-
tality benefit in patients with sCAP, despite evidence of
biological activity as an anticoagulant protein.
APC has antithrombotic, anti-inflammatory, and pro-
fibrinolytic properties that might be beneficial in the
treatment of sCAP. The PROWESS trial, conducted in 1690
patients with severe sepsis, reported that treatment with
APC (drotrecogin alfa activated [Xigris]) significantly
reduced mortality in patients with severe sepsis but may be
associated with an increased risk of bleeding [13]. In
contrast, the PROWESS SHOCK trial conducted in 1697
760 T. Welte et al.patients with septic shock showed that APC did not reduce
mortality significantly after 28 or 90 days [14]. In 2011
drotrecogin alfa activated was withdrawn from the market.
The anti-inflammatory properties of corticosteroids may
reduce the intense pro-inflammatory cytokine response and
thus modify the occurrence and severity of organ failures.
However, results to date have been inconclusive [15].
Meijvis et al. [16] recently reported that non-
immunocompromised CAP patients had significantly
shorter length of hospital stays (without excess complica-
tions) when treated with dexamethasone in a randomised,
double-blind, placebo-controlled clinical trial. Based on the
results from four studies evaluating the use of corticoste-
roids for sCAP, Salluh et al. [17] did not recommend the use
of corticosteroids as adjunctive therapy for this indication.
In patients with septic shock, the large CORTICUS trial (499
patients) found that hydrocortisone did not improve sur-
vival or reversal of shock [18].
TLR4 (toll-like receptor 4) is a receptor stimulated pri-
marily by endotoxin leading to the production of pro-
inflammatory cytokines. Blocking this receptor may
possibly reduce the pro-inflammatory response. However,
in a phase III study in 1961 patients with severe sepsis the
TLR4 antagonist Eritoran did not show reduced 28-day
mortality compared to placebo [19].
In addition various types of intravenous immunoglobulin
preparations have been investigated as possible adjunctive
treatment for sepsis. Pentaglobin with 12% IgM, 12% IgA
and 76% IgG is currently the sole approved immunoglobulin
preparation enriched with IgM having a variety of anti-
bacterial and anti-inflammatory properties. It can
neutralise bacterial endo- and exotoxins [20,21], increase
opsonisation and bacterial phagocytosis [22], and can
enhance bacterial lysis due to specific complement acti-
vation [23]. It can also exhibit anti-inflammatory and
immunomodulatory effects via scavenging of excessively
activated complement factors [24], and modulation of the
immune response via Fcg receptor interactions in case of
severe bacterial infections [25].
The majority of clinical trials with Pentaglobin have
been performed thus far in patients with severe bacterial
infections and not explicitly in sCAP patients.
Two relevant systematic reviews of clinical trials
concluded that immunoglobulins and in particular the
immunoglobulin preparation enriched with IgM, are of
benefit in adult and older paediatric sepsis patients [26,27].
Kreymann et al. [26] conducted a comprehensive sys-
tematic review of all published trials examining the effect
of various polyclonal immunoglobulin preparations on
mortality in patients with sepsis or septic shock. 15 trials in
adults or children and 12 in on-term or preterm neonates
(27 trials in 2202 patients in total) were examined, in which
the estimate of the pooled risk revealed a significant rela-
tive reduction of overall mortality of 21% and 44%,
respectively. In the IgM-enriched immunoglobulin prepara-
tion subgroups, a notably higher, but not statistically sig-
nificant reduction in overall mortality was observed with a
34% mortality reduction in adults or children and 50% in
neonates. Alejandria et al. [27] conducted a comprehensive
systematic review of all published trials examining the ef-
fects of all intravenous immunoglobulins (IVIG) on mortality
and duration of hospitalisation in patients with sepsis orseptic shock. Subgroup analysis of 10 polyclonal IVIG trials
in adults (nZ 1430) and 7 trials on IgM-enriched polyclonal
IVIGs (n Z 528) showed significant reductions in mortality
compared to placebo or no intervention (relative risk [RR]
0.81; 95% confidence interval [CI]) 0.70 to 0.93 and RR 0.66;
95% CI 0.51 to 0.85, respectively). A sensitivity analysis of
only those trials with a low risk of bias showed no reduction
in mortality in adults irrespective of treatment with poly-
clonal IVIG or the IgM-enriched immunoglobulin prepara-
tion. The CIGMA Study will provide further data to elucidate
the controversial results of these two meta-analyses.
A large study with 653 patients with severe sepsis (SBITS
trial) showed that the administration of polyclonal IVIG
preparations (not enriched with IgM) could not reduce the
mortality rate [28]. For that reason in the German Sepsis
Guideline [29] IgM-enriched immunoglobulins could be
considered for patients with severe sepsis and septic shock,
whereas IVIGs not enriched with IgM are not recommended.
Berlot et al. [30] have reported that the efficacy of
Pentaglobin in patients with severe sepsis and septic shock
is time dependent, similar to broad spectrum antibiotics.
They found that every 24 h of delay in administration of IgM
resulted in a linear increase in mortality by 2.8%. This
finding may be an important factor to explain the incon-
sistent findings reported from systematic reviews.
The question if reduced IgM levels are a risk factor for
severe infections was recently addressed in different pop-
ulations including patients with CAP, influenza (H1N1)
pdm09 and sepsis [31e34]. Results in patients with severe
sepsis progressing to septic shock and in patients with viral
infections showed that non-survivors had lower levels of IgM
compared to survivors [34,32]. De la Torre et al. [31]
described for the first time that CAP patients had lower
immunoglobulin levels compared with healthy volunteers.
Immunoglobulin levels were especially low at the time of
diagnosis, and in patients infected with S. pneumoniae.
Immunoglobulin levels are also to be measured in a sub-
group of the patients in the CIGMA Study.
The novel product BT086 was developed to generate a
preparation with double the content of IgM compared to
Pentaglobin. BT086 contains approximately 23% IgM, 23%
IgA, and 54% IgG compared to Pentaglobin (12% IgM, 12%
IgA, and 76% IgG). In addition, a new manufacturing process
for BT086 was established to obtain more native immuno-
globulins with highly active binding sites.
First-in-man clinical data are available fromaphase I dose
escalation study performed to investigate the safety, toler-
ability, and pharmacokinetics of BT086 after single and
repeated doses given as intravenous infusions to healthy
subjects [35,36]. Administration of BT086 was well toler-
ated. Intravenous single infusion of BT086 (mean baseline
value 105.5 mg/dL) led to the expected increase of IgM of up
to 102 mg/dL [35]. With repeated infusions, 5 administra-
tions of one dosage of BT086 on 5 consecutive days, (mean
IgMbaseline concentrations 123.8mg/dL), IgMCmax reached
172.4 mg/dL and a t1/2 was estimated at about 7.6 days [36].
BT086 has a broad range of activity against clinically
relevant gram negative and gram positive bacteria. In the
phase I study specific antibody activities against the
following indicator pathogens were measured: E. coli, C.
albicans, and the sCAP pathogen S. pneumoniae . Specific
antibody activities were increased in the serum of healthy
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control group (unpublished results).
To further evaluate BT086, the CIGMA Study in sCAP
patients has been initiated and is introduced here. The
sponsor of the study is Biotest (Dreieich, Germany) and has
appointed Accovion Clinical Research Organisation (CRO) to
manage the CIGMA study in all countries.Methods and patient population
160 patients are planned to be included in the CIGMA Study
(the original sample size of 82 patients was increased to 160
patients after an interim analysis on the first 40 patients).
Eligible patients are to be diagnosed with sCAP based on
clinical and radiological findings, be in need of endotra-
cheal ventilation, and have received antibiotic therapy.
For a correct allocation of hospitalised patients, the
Infectious Disease Society of America (IDSA) and the
American Thoracic Society (ATS) have issued guidelines on
the management of CAP that include severity criteria to
identify those patients that should receive ICU care [37].
The major criteria of the IDSA/ATS guidelines refer to pa-
tients with acute respiratory failure requiring invasive
endotracheal ventilation or with septic shock.
Inclusion and exclusion criteria in the CIGMA Study have
been developed on the basis of the CAP/sCAP criteria of the
IDSA/ATS guidelines [37], the Food and Drug Administra-
tion’s Guidance for Industry [38], and the German S3
Guidelines [39].
The key inclusion criteria are:
 Patient must have at least one of the following signs and
symptoms of pneumonia: new or increased cough; pro-
duction of purulent sputum or change in sputum charac-
teristics; dyspnoea or tachypnoea (respiratory rate >20
breaths/minute); pleuritic chest pain; auscultatory find-
ings on pulmonary examination of rales and/or crackles
and/orevidenceofpulmonary consolidation (e.g.dullness
on percussion, bronchial breath sounds, or egophony).
 Radiological (or other imaging technique) evidence of
(an) infiltrate(s) consistent with bacterial pneumonia.
 Major sCAP criterion: need for endotracheal ventilation.
 Pneumonia has been acquired outside hospital. In
hospital-admitted patients, pneumonia has been diag-
nosed a maximum of 72 h after admission. Patients from
nursing homes or similar institutions are eligible. Male or
female patients aged 18 years or older.
 Patient receiving adequate antibiotic treatment for
pneumonia.
 Prior to endotracheal ventilation and therapy, the pa-
tient must have at least one of the following two signs of
inflammation: fever/hypothermia or white blood cell
(WBC) count >10,000/mm3 or WBC <4500/mm3.
 Treatment of patient with BT086 must start within 12 h
but not earlier than 1 h after start of endotracheal
ventilation.
The key exclusion criteria are:
 Patients with suspected hospital-acquired pneumonia.
 Severe lung diseases interfering with sCAP therapy. Presence of other severe diseases impairing life expec-
tancy (e.g. patients are not expected to survive 28 days
given their pre-existing uncorrectable medical
condition).
 Patients with neutrophil count <1000/mm3 or platelet
count <50,000/mm3.
Primary endpoint
The primary endpoint of the study is the increase of
ventilator-free days (VFDs). VFDs are defined as the number
of days between successful extubation from endotracheal
ventilation and day 28 after enrolment of the patient into
the study. VFDs are defined as “0” if the patient dies before
day 28 or in case endotracheal ventilation is stopped at day
28 or later. VFDs are assessed in mechanically ventilated
sCAP patients receiving appropriate standard of care
treatment in addition to either BT086 or placebo.
Secondary endpoints
Secondary endpoints include VFDs in surviving patients, 28-
day all-cause mortality, 28-day pneumonia-cause mortality,
time to discharge from ICU, time to discharge from hospi-
tal, Sequential Organ Failure Assessment (SOFA) Score,
Glasgow Coma Score and vasopressor-free days.
Other objectives
Safety parameters are to be collected in all patients to
ensure accurate monitoring of safety and tolerability.
Pharmacodynamic and pharmacokinetic parameters are to
be measured in a subgroup of patients.
Dose selection
Dose selection was based on results from Rodriguez et al.
[40] and the phase I first-in-man study [35,36]. In this study,
a BT086 dose of 42 mg IgM/kg body weight demonstrated
reproducible dose-dependent elevated plasma levels of IgM
after repeated application. Therefore, this dose was
selected for the CIGMA Study, and is to be administered for
5 consecutive days.
Design
The CIGMA Study is a multicentre, randomised, placebo-
controlled, double-blind, parallel-group, adaptive group-
sequential phase II study. The purpose of the study is to
determine the efficacy and safety of BT086 as an adjunctive
treatment in mechanically ventilated patients with sCAP.
In this trial, BT086 is to be given in addition to the best
standard of treatment and is to be compared against a
control arm consisting of the best standard of treatment
and placebo (1% albumin). Thus far, no approved treatment
has demonstrated efficacy in addition to the best standard
of treatment in sCAP patients that could be used as an
active comparator in this study. Eligible patients are to be
randomised 1:1 to treatment with BT086 or placebo. Infu-
sion with BT086 is to begin between 1 h and 12 h after
starting endotracheal ventilation. During the treatment
762 T. Welte et al.phase, patients are to be treated with 42 mg IgM/kg body
weight or equal volume of 1% albumin for 5 consecutive
days (Fig. 1). Patients are to remain in the CIGMA Study up
to day 28 or hospital discharge, whichever occurs first.
Since ventilation and weaning procedures might differ
among sites and countries, a study-specific guidance on
endotracheal ventilation and weaning was developed for
this trial.
This guidance is mainly based on the concept of lung
protective ventilation [41]. The main goals of mechanical
ventilation are to achieve adequate oxygenation; PaO2
target level >65 mm Hg; appropriate alveolar ventilation,
PaCO2 target level intended to achieve arterial pH be-
tween 7.25 and 7.45 with minimal risk of barotrauma,
volutrauma, or atelectrauma; end-inspiratory plateau
pressure ideally below 30 cm H2O; and use of minimal
level of positive end-expiratory pressure (PEEP). Minimal
haemodynamic deterioration can be achieved by avoiding
excessive ventilation and PEEP, and by using the minimal
necessary level of analgesia-sedation. Patients are to be
evaluated daily for clinical stability, normal conscious-
ness, and improvement of respiratory failure to decide
whether to withdraw mechanical ventilation and to start
a spontaneous breathing trial [42] (SBT). The duration of
the SBT is to be between 30 and 120 min; the presence
and persistence of criteria for SBT failure is to be
assessed during the trial.
The decision to extubate or to reconnect a patient to the
ventilator is to be based on the absence of signs of SBT
failure [43] after 30e120 min, adequate mental status, and
cough with ability to expectorate. If these conditions are
not fulfilled, patients are to be reconnected to the venti-
lator. Subsequent attempts are to be performed daily pro-
vided that patients still fulfil criteria for the withdrawal of
mechanical ventilation. After extubation, patients are to
receive Venturi oxygen therapy.Data Safety Monitoring Board
For this phase II study, the sponsor Biotest established a
Data Safety Monitoring Board (DSMB) for the following
reasons:
 The study is to be conducted in patients with sCAP, a
life-threatening disease with high rates of mortality.
 The study is to include blinded study treatment groups.
 The study is to be conducted in patients unable to pro-
vide informed consent by themselves.Figure 1 All 160 patients were to be randomised in a 1:1 ratio t
tients were to be screened and randomised into the study between
randomisation patients were to be treated for 5 days with 42 mg
remain in the trial until day 28 or discharge from hospital, whicheStatistical methods
All statistical methods, the primary and secondary end-
points, all variables, as well as the statistical methods to be
used for both interim analyses and the final analysis are
described a priori in the study protocol and were detailed in
the statistical analysis plan.
Analysis of VFDs
Treatment effects on VFDs may be attributed to changes in
mortality or to changes in the duration of ventilation in
survivors; as a result, differences between two treatments
cannot be meaningfully expressed in terms of mean or
median differences. Therefore, statistical tests powered to
detect a shift in means or medians do not appropriately
assess a treatment effect in a composite endpoint like
VFDs.
The statistical approach in this study is based on the
concept of stochastic dominance of distribution functions.
The probabilistic index [44] (PI) is used to quantify the
probability that any patient in a given treatment group has
a better outcome than any patient in the other group. As
patients benefit from a treatment that increases their
chances to survive or to have a shorter duration of venti-
lation, the cumulated frequency distribution of VFDs (from
0 to 28) in the superior treatment is located below the
frequency distribution of the inferior treatment (Fig. 2). If
two treatments are identical, a patient has an equal chance
to benefit from one or from the other, expressed by a PI of
0.5. Values above 0.5 indicate that a treatment is superior,
values below 0.5 indicate inferiority. The PI can be derived
from ManneWhitney’s U-statistic, divided by the number of
all possible pairs of observations from each group. The
corresponding statistical test is the Wilcoxon-Mann-
Whitney-test. Asymptotically, the PI is normally distrib-
uted allowing easy computation of CIs.
Group sequential-adaptive design
To adapt the study to accumulating data, a group-
sequential adaptive design was chosen which allows
design modifications such as sample size re-estimation or
planning of further analyses based on interim results. This
design combines features of a classic group-sequential
design with the theory of adaptive designs based on com-
bination tests. Group-sequential designs allow to perform
pre-planned interim analyses on the accumulating data ando BT086 or to placebo (1% albumin). Pretreatment phase: pa-
1 and 12 h after starting ventilation. Treatment phase: after
IgM/kg bw/day or placebo. Follow-up phase: patients were to
ver occurred first.
Figure 2 Treatment A, upper curve, shows a cumulative distribution of ventilator-free days (VFDs) in a patient population with a
mean value of 6 VFDs (standard deviation Z 6.8). The probability of zero VFDs due to fatal events or 28 VFDs or more is 40%.
Treatment B curve shows the cumulated distribution of VFDs in a population with a higher chance of surviving or more VFDs: the
probability of zero VFDs is 25% with a mean value of 8.9 VFDs (standard deviationZ 7.5). The probabilistic index is 0.62 indicating
that any patient on treatment B has a 62% chance of more VFDs (or survival) compared with any patient on treatment A.
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met or if it is unlikely that the study will reach its objec-
tives. Because each interim look increases the risk of a false
positive decision, the critical values of the tests (stopping
boundaries) are adjusted accordingly. More flexibility can
be gained if the study stages are evaluated separately and
an adaptive combination test used to combine the stage-
wise results. In this study, a combination test based on the
inverse normal method is used to combine the stage-wise
test-statistics [45]. This combination test allows to use the
boundaries of a classic group-sequential design: to preserve
the overall level of significance (2.5%, one-sided), an alpha-
spending approach with O’Brien-Fleming boundaries to
adjust critical values and significance levels of the interim
and final analyses (alpha 1 Z 0.23%, alpha 2 Z 2.41%) was
used. One-sided statistical tests were chosen to avoid
contradictory results in the interim and the final analyses
leading to an overall significant but not clinically mean-
ingful result. It is also planned that the study can be
stopped for futility if the conditional power (probability of
success in case of a true treatment effect) is below 10%.
Sample size estimation
The sample size of the study was planned based on an ex-
pected mean difference between BT086 and placebo of 2
VFDs and a standard deviation (SD) of 3 VFDs. Using
Noether’s formula for the sample size of the Wilcoxon-
Mann-Whitney-test, the sample size calculation for the
group-sequential design resulted in a sample size of 82
patients who are to be randomised in a 1:1 allocation ratio[46] to achieve a power of at least 80%. 40 patients were
recruited in the first stage of the study.Sample size re-estimation based on conditional
power
After the first interim analysis, the sample size for the
second stage was re-estimated based on a conditional
power of 80% to confirm a true treatment effect of BT086
on VFDs. The conditional power was determined by the PI
and the corresponding p-value in the first stage, and the
significance level and sample size of the second stage.
Calculations were done using an R program.Evaluation of secondary endpoints and other
variables
Demographic and medical background data, secondary
endpoints and safety variables are to be analysed by means
of descriptive and exploratory methods. Continuous vari-
ables are to be summarised by the number of patients,
mean, SD, median, quartiles, and range. Categorical vari-
ables are to be summarised using number and percentages
by category. Medical terms and adverse events are to be
coded using the Medical Dictionary for Regulatory Activities
(Version 15.0) and summarised according to system organ
class and preferred term. Concomitant medications are to
be coded using the World Health Organization e Drug Dic-
tionary and summarised according to the anatomical ther-
apeutical chemical (ATC) terminology.
764 T. Welte et al.General statistical concepts
All statistical analyses are to be performed in a modified
intent-to-treat population which includes all randomised
patients with at least one post-baseline observation of the
primary variable.
The SAS system is to be used for statistical analyses.
nQuery Advisor 7.0 [47] and ADDPLAN 5.0 [48] were used
for the sample size calculations for the group-sequential
adaptive design. An R program developed by one of the
authors was used to perform the conditional power
calculations.Interim analyses
To terminate the study early in case of superiority of BT086
or in case of futility, or to evaluate the assumptions of the
sample size estimation and to adjust the sample size, an
adaptive group-sequential design was used.
The first interim analysis was planned to be performed
after 20 patients per group (in total 40 patients) have
completed treatment. The sample size of the second stage
of the trial was determined based on a weighted average of
the expectations before the start of the study and the
actual results of the first stage.
A second interim analysis was performed after 100 pa-
tients completed treatment. The second interim analysis
allowed termination of the study, where appropriate, and
to claim statistically significant superiority of BT086 over
placebo, if the observed p-value for the primary variable
(VFDs) in this analysis was below the conditional type I error
rate determined by means of the recursive combination
test method.
Based on the results from the second interim analysis, a
statistician was to recommend whether the study should be
stopped in the case of a significant result, or whether it
should continue up to the planned sample size.Study status as of June 2014
At the beginning of the trial, study sites were opened in
Germany and Spain. The first patient was enrolled on 04
October 2011.
The first interim analysis was completed on 07 March
2013, and was performed after the first 40 patients
completed the CIGMA Study. The cut-off date for this
analysis was defined as the date when data for the primary
endpoint, VFDs, became available.
As a result of the first interim analysis, the trial was not
terminated early due to superiority or futility of BT086.
Results from the first interim analysis showed that the
variability of the VFDs quantified by the SD in the interim
study population was an overall SD of 9.61 VFDs. A sample
size of 120 patients (60 on BT086 and 60 on placebo) was
estimated for the second stage of the study based on con-
ditional power after results from the first stage. As a result,
the total number of patients to demonstrate statistical
significance was recalculated to 160 patients. With this
sample size, statistical significance to demonstrate the
efficacy of BT086 was expected to be achieved.After the first interim analysis, new sites were added in
Germany, the UK, and Belgium.
A second interim analysis was planned to be performed
after results from the first 60 randomised patients in the
second stage (100 patients in total) became available. The
second interim analysis took place on the 31 March 2014. As
a result of the second interim analysis, the trial was not
terminated early.
Publication of the interim and final results is planned
after completion of the study.
Unblinded data sets have been reviewed by the DSMB for
the first six consecutive patients, and for the 12, 24, and 36
patients thereafter who completed the study. No safety
issues have been raised by the DSMB members at any time.
As of 03 June 2014, 124 patients have been randomised
in the study.Discussion
Patients affected by sepsis have a high mortality rate in
spite of the wide availability of antibiotics. Furthermore,
widespread resistance of pathogens to antibiotics has
increased the medical need to look for alternate treat-
ments shifting the focus to host response.
During the last two decades, the efficacy and safety of
several novel agents to treat sepsis have been evaluated in
many clinical trials; however, none of the agents tested has
significantly reduced the high mortality rates [49]. Failure
was attributed to the heterogeneity of septic patients or
sepsis [49]. A very large population of patients develops
sepsis from sCAP [50]. This indication was chosen for the
CIGMA Study with the aim to increase homogeneity within
this patient population. To achieve this goal, the CIGMA
Study is restricted to mechanically-ventilated sCAP pa-
tients. Patients with sCAP have very high mortality rates,
are in the ICU and on endotracheal ventilation.
A literature search of different randomised controlled
clinical trials in ICUs reported that relatively few trials (10/
72) using mortality as a primary outcome show a beneficial
impact of the intervention on the survival of critically ill
patients [51]. While mortality may be the most robust
outcome for patients with sCAP, other outcomes including
VFDs and quality-adjusted life-years may also be suitable,
and could reduce the sample size requirements [52].
VFDs are clinical endpoints that combine mortality and
duration of ventilation in survivors [53]. In addition, VFDs
provide information about the length of ventilation, an
important aspect in this patient population because the
longer patients are ventilated, the greater the risk of
complications and additional infections. VFDs increase the
patient’s quality of life and decrease treatment costs.
In the CIGMA Study, VFDs are the primary endpoint and
28 day mortality is one of the secondary endpoints.
Ventilation and weaning procedures might differ among
sites and countries. Therefore for the CIGMA Study, a me-
chanical ventilation protocol, including weaning pro-
cedures, was developed and implemented in all study
centres to standardise the ventilation procedure.
Limited information about the efficacy and safety of
BT086 was available during the study design phase. An
adaptive study design was chosen for the CIGMA Study
The CIGMA study: treating severe community-acquired pneumonia 765because it allows to re-estimate the sample size based on
the observed variance and treatment effect or to stop the
study early in case of overwhelming efficacy or futility after
an interim analysis.
Clinical studies generally include patients at different
stages in the pathological process. The degree and nature
of the inflammatory response vary among patients, and
over time, within the same patient [49]. Vincent et al. [49]
concluded that the timing of immunomodulatory therapy is
likely to be crucial for a successful study design, an aspect
that has not been explored enough in past sepsis trials.
Berlot et al. [30] reported that the efficacy of the IgM-
enriched immunoglobulin Pentaglobin in patients with
severe sepsis and septic shock is time dependent; every
24 h of delay in administration resulted in a linear increase
in mortality by 2.8%. In light of Berlot’s findings, it can be
assumed that the administration of BT086 early in the
clinical course of a severe infection such as sCAP may
provide an additional treatment effect for these patients.
Given these findings, in the CIGMA Study, patients were to
start treatment within 12 h after starting endotracheal
ventilation.
Another important parameter influencing efficacy in
sepsis trials is adequate dosing of the medication [49]. The
dose for the CIGMA Study was chosen based on results from
the phase I first-in-man study with BT086 where a dose of
42 mg IgM/kg body weight demonstrated reproducible and
dose dependant results [35,36]. The equivalent dosage of
IgM was used in the randomised controlled trial with
Pentaglobin performed by Rodriguez et al. [40]. Results
from this trial showed clinical benefit in terms of reduced
mortality compared with the control group. In the first-in-
man study with BT086 [36] and in the study with
Pentaglobin led by Rodriguez [40], patients were treated
for 5 days. Similarly, BT086 is to be infused for 5 consecu-
tive days in the CIGMA Study.
Pentaglobin has shown efficacy as adjuvant therapy to
treat severe bacterial infections when used in addition to
antibiotic therapy [26]. In addition, measurements of IgM
levels in patients with sepsis and viral infections showed
that non-survivors had lower levels of IgM compared to
survivors [34,32]. These results highlight the importance of
IgM in the host defense mechanism. IgM is the most
important class of immunoglobulins in the defense of bac-
terial infections and it occurs first in the immune response.
Because of its pentameric structure, IgM may be superior to
IgG in toxin neutralisation and bacterial agglutination. IgM
is more effective than IgG at killing bacteria because it
activates up to 400 times more complement than IgG [23],
and it has been reported to be up to 1000 times more active
in the opsonisation of bacteria [23].
In view of the fact that IgM plays an important role in the
host response, the concentration of IgM in BT086 has been
increased to approximately 23% compared to that of 12% in
Pentaglobin. In addition, a new manufacturing process for
BT086 was established to obtain more native immunoglob-
ulins with highly active binding sites. Data from the first-in-
man study with BT086 showed that the administration of
BT086 resulted in the expected increases in serum IgM, and
was safe and well tolerated [35,36]. BT086 has a broad
range of activity against clinically relevant gram negative
and gram positive bacteria. Specific antibody activitiesagainst the indicator pathogens E. coli, C. albicans, and the
sCAP pathogen Streptococcus pneumoniae were measured
in the serum of healthy subjects after treatment with
BT086 (unpublished results).
In view of the high mortality rates combined with
increased widespread resistance of pathogens to antibi-
otics, the high unmet medical need in patients with sepsis
and sCAP warrant the exploration of alternate therapies to
treat sCAP, e.g. host-targeted treatments.
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